Unknown PHASE2 INTERVENTIONAL 1-arm NCT03556566

Open Label Immunotherapy Trial for Ovarian Cancer (V3-OVA)

Open Label, One-arm, 3-month Study of Once-daily Tablet of V3-OVA as Immunotherapy of Ovarian Cancer

Sponsor: Immunitor LLC

Interventions Tableted vaccine (V3-OVA) containing ovarian cancer antigens

Updated 7 times since 2018 Last updated: Aug 29, 2019 Started: Jul 1, 2018 Primary completion: Nov 30, 2019 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ovarian Cancer and is currently ongoing. Immunitor LLC leads this study, which shows 7 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Sep 2019 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Sep 2018 — Sep 2019 [monthly]

Recruiting PHASE2
Jul 2018 — Sep 2018 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immunitor LLC

Data source: Immunitor LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ulaanbaatar, Mongolia